The FDA Wants Tavneos Pulled, but Getting It Off the Market Won't Be Simple
Health·November 1, 2026

The U.S. Food and Drug Administration wants to revoke its approval of Tavneos, arguing that the drug was cleared on the strength of study data that were manipulated. If the agency follows through, it would remove a medicine that patients are currently taking, which raises an obvious question: should they keep getting it while the matter is settled?
Withdrawing an approval is rarely a switch the FDA can flip. The process generally involves formal notice to the manufacturer, a chance to respond, and often a hearing before the decision becomes final. That gives the company room to contest the agency's findings, and it means the drug may stay on the market for some time even after the FDA has taken a position.
For patients and their doctors, that gap is the practical problem. A treatment can be effective for some people and still rest on a foundation that regulators now say was compromised. Clinicians will have to weigh the risk of abruptly stopping a therapy against the reliability of the evidence behind it.
The core issue is trust in the data. If the studies that justified approval cannot be relied on, the agency has to decide whether the drug's benefits were ever properly shown. Patients should talk with their prescribing doctor before changing or stopping treatment, and should watch for further FDA action that will spell out what happens next.
Reporting based on an external source.